Genetic Studies of Chronic Active Epstein-Barr Disease

  • STATUS
    Recruiting
  • participants needed
    300
  • sponsor
    National Institute of Allergy and Infectious Diseases (NIAID)
Updated on 30 July 2021

Summary

Epstein-Barr virus (EBV) is a member of the human herpes virus family that infects more than 95 percent of the U.S. population. Most infections occur in childhood and cause no symptoms; in adolescents and adults, EBV often causes infectious mononucleosis. It has also been associated with certain forms of cancer. Chronic Epstein-Barr virus (CAEBV) is a rare disease, primarily of children and young adults, that leads to life-threatening infections.

This study seeks to identify genetic mutations responsible for CAEBV. A secondary goal is to learn more about the natural history of CAEBV.

The study will examine blood and tissue samples from up to 50 patients (age 3 and above) with CAEBV and up to 150 of their relatives (age 1 and above). Autopsy samples may be included in the study. Up to 300 anonymous blood samples from the NIH Clinical Center Blood Transfusion Medicine will also be examined for comparison.

No more than 450 milligrams (30 tablespoons) of blood per 8 weeks will be drawn from adult patients, and no more than 7 milliliters per kilogram of blood per 8 weeks will be drawn from patients under age 18. Local health care providers will refer patients to the study and will obtain the samples. Some patients may also be seen at the NIH Clinical Center. Those patients will have a full medical history and physical examination, along with chest X-ray, blood counts, blood chemistry, EBV serologies, and viral load. Other tests, such as CT scan or MRI, may be performed if medically indicated. Patients will be asked to undergo leukapheresis.

In vitro tests on the blood or tissue samples will include analysis for proteins or genes that are involved in the immune response; cloning of portions of patient DNA; transformation of B cells with EBV; measurement of the ability of patient blood cells to kill EBV-infected cells; determination of lymphocyte subsets; and determination of antibodies to EBV or other herpes viruses.

If a genetic cause for CAEBV is found, the investigators will be available to discuss the results with patients in person or by telephone. Genetic indications of risk for other diseases will also be discussed with patients.

Description

Patients with chronic active Epstein-Barr virus (CAEBV) have (a) an illness that began as a primary infection with EBV or markedly elevated titers of antibodies to EBV, (b) histological evidence of organ disease, and (c) elevated EBV DNA levels in the blood or EBV DNA or proteins in affected tissues. This is primarily a disease of children and young adults. Many of these patients develop hypogammaglobulinemia or pancytopenia and death is frequently due to opportunistic infections or B or T cell lymphoproliferative disease. The primary goal of this study is to identify genetic mutations responsible for CAEBV. The secondary goal of this study is to learn more about the natural history of CAEBV. Blood samples or available tissues (e.g. previous biopsy or autopsy material) from patients with CAEBV and their relatives will be analyzed to identify disease genes that are mutated in this population. In addition, some of the patients will be invited to come for evaluation at the NIH Clinical Center. At that time medically indicated studies of disease progression will be performed. Serial virologic and immunologic studies will be performed. Eligible relatives of patients will be studied to compare the gene(s) associated with CAEBV in patients with the gene(s) in their relatives. Knowledge gained from this study has the potential of providing insights into the immunologic control of EBV infections. In addition, identification of the molecular mechanisms for CAEBV may provide insights leading to improved treatments for this disease.

Details
Condition EPSTEIN BARR VIRUS INFECTION, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus, Chronic Active Epstein-Barr Virus
Clinical Study IdentifierNCT00032513
SponsorNational Institute of Allergy and Infectious Diseases (NIAID)
Last Modified on30 July 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note